Reasons for prolonged time for diagnostic workup for stage I-II lung cancer and estimated effect of applying an optimized pathway for diagnostic procedures

Trine Stokstad 1,2*, Sveinung Sørhaug 3,4, Tore Amundsen 3,4 and Bjørn H. Grønberg 1,5

Abstract

Background: Minimizing the time until start of cancer treatment is a political goal. In Norway, the target time for lung cancer is 42 days. The aim of this study was to identify reasons for delays and estimate the effect on the timelines when applying an optimal diagnostic pathway.

Methods: Retrospective review of medical records of lung cancer patients, with stage I-II at baseline CT, receiving curative treatment (n = 100) at a regional cancer center in Norway.

Results: Only 40% started treatment within 42 days. The most important delays were late referral to PET CT (n = 27) and exercise test (n = 16); repeated diagnostic procedures because bronchoscopy failed (n = 15); and need for further investigations after PET CT (n = 11). The time from referral to PET CT until the final report was 20.5 days in median.

Applying current waiting time for PET CT (≤7 days), 48% would have started treatment within 42 days (p = 0.254).

“Optimal pathway” was defined as 1) referral to PET CT and exercise test immediately after the CT scan and hospital visit, 2) tumor board discussion to decide diagnostic strategy and treatment, 3) referral to surgery or curative radiotherapy, 4) tissue sampling while waiting to start treatment. Applying the optimal pathway, current waiting time for PET CT and observed waiting times for the other procedures, 80% of patients could have started treatment within 42 days (p < 0.001), and the number of tissue sampling procedures could have been reduced from 112 to 92 (~16%).

Conclusion: Changing the sequence of investigations would significantly reduce the time until start of treatment in curative lung cancer patients at our hospital and reduce the resources needed.

Keywords: Pathway, Timeliness, Diagnostic efficacy, Organization

Background

Long intervals for completion of diagnostic workup and start of treatment causes distress among cancer patients [1], and is conceived as a medical risk that may negatively impact survival [2–4]. Thus, it is a political goal that diagnostic workup for suspected cancer should be performed efficiently and with no delays except those who are due to medical reasons. Consequently, programs for timely care have been developed, e.g. the two-week-wait referral pathway in the UK [5, 6], and the national cancer pathway intervention in Denmark [7, 8].

Diagnostic workup for lung cancer has become complex due to the increasing number of treatment options. More patients are eligible for potentially curative therapy due to less invasive surgery and advanced radiotherapy techniques but require more extensive tissue sampling for correct staging of disease, and targeted therapies are selected according to molecular profiling of tissue samples. Thus, a multidisciplinary approach including sufficient resources for imaging, tissue sampling and analyses is required, necessitating a good organization across departments and health care levels.
In Norway, current national guidelines recommend that a patients’ first hospital visit should take place within 7 calendar days after the hospital receives a referral letter for suspected lung cancer; a treatment decision should be made within 28 days; systemic therapy should start within 35 days; and surgery or radiotherapy within 42 days [9]. It is a goal that 70% start treatment within these target timeframes. The timeframes are consensus-based and were met with skepticism. A common opinion among physicians was that it would not be possible to achieve these goals with allocating more resources to the hospitals.

There are few studies of the logistics of lung cancer diagnostic work-up, and mechanisms for delays are poorly described [10]. In a previous study, we found that only a minority of lung cancer patients started treatment within the recommended timeframes at our hospital [11]. There was a need to better understand why delays occurred, and to assess whether the recommended timeframes could realistically be met without increasing the budgets of the involved hospital departments. The aims of this study were to identify reasons for delays, define an optimal pathway for diagnostic procedures, and estimate the effect on the timelines of applying this pathway. Due to the heterogeneity and complexity of lung cancer patients in general, we limited the present study to patients presenting with stage I-II on the base-line CT scan who were eligible for potentially curative treatment.

Methods
Study setting
St. Olav's Hospital, Trondheim University Hospital, in Trondheim, Norway, is the primary hospital for 380,000 people, the regional cancer center for the Central Norway Health Region with a population of approximately 700,000 people, and the only hospital in the region to offer lung cancer surgery and positron emission tomography computer tomography (PET CT) (since October 2013). Lung cancer diagnosis take place at the Department of Thoracic Medicine by pulmonologists specializing in lung cancer diagnosis and treatment, and they also offer systemic therapy; the Cancer Department provides radiotherapy, oncologists are trained in both medical oncology and radiotherapy; and surgery take place in the Department of Cardio-Thoracic Surgery. A tumor board of pulmonologists, thoracic surgeons, oncologists, thoracic radiologists, specialists in nuclear medicine, pathologists and a patient coordinator, meets every week.

Study design, patients and data collection
We performed a retrospective analysis of the individual hospital medical records of all lung cancer patients presenting with stage I-II disease at the baseline CT scan, who were diagnosed at the Department of Thoracic Medicine, and who underwent surgery or curative radiotherapy at St. Olav's hospital between January 1, 2011 until December 31, 2013. More details about the conduct of our study is included in a previous publication [11]. Patients with a delay of ≥3 days caused by comorbidity, intercurrent disease, or the patients’ wish were excluded. Stage of disease was assessed according to the 7th edition of the TNM classification of lung cancer [12].

Exercise tests included stair-climbing test, six-minute walk-test, and cardiopulmonary exercise test [13]. We defined tissue diagnostic method as either bronchoscopy, bronchoscopy and endobronchial ultrasound transbronchial aspiration (EBUS-TBNA), or transthoracic needle biopsy (TTNB); and that the method “failed” when the diagnosis was confirmed by subsequently using another method, or the patient underwent both bronchoscopy and bronchoscopy with EBUS-TBNA.

We registered a) the date when a referral letter for suspected lung cancer was registered at the Department of Thoracic Medicine, or the date when diagnostic workup for suspected LC was initiated in a patient with a single pulmonary nodule who had been previously observed (“Receiving a referral letter”); b) the date of the first appointment with a pulmonologist (“First consultation”); c) for each diagnostic work-up procedure: c) type of procedure, d) date of referral to the procedure, c) the date it took place, and f) the date when the result of a procedure was documented in the patient’s medical record; g) the date a treatment decision was documented in the patient's medical record; h) the date of surgery or first day of radiotherapy or chemotherapy (“Start of treatment”). “Time to treatment” was defined as interval in calendar days from receiving a referral letter for suspected lung cancer until start of treatment; “Timely”, ≤ 42 days; “Untimely”, > 42 days. Finally, we calculated the median times for referral to each diagnostic procedure until the final report was available.

Data analysis
The sequences of actions were ordered and intervals in calendar days were calculated: from receiving a referral letter until first consultation; from first consultation until referral for diagnostic work-up procedure(s); from referral to a procedure until the result was available in the electronic medical record; from the result of a procedure until this result was actioned upon (by referral to another procedure or making a treatment decision); from treatment decision until start of treatment.

Models for simulating improvements were built by changing the sequence of actions. The numbers who could start timely treatment were compared using logistic regression. Analyses were performed using the Stata/IC 14.2 package for Windows.
Results

Patient characteristics
Four hundred fifty-four patients were diagnosed with lung cancer between January 1, 2011 and December 31, 2013. Five patients declined inclusion [11], and among the other 449 patients, 150 presented with preliminary stage I or II. Twenty-six patients were excluded since they were ineligible for curative treatment; and another 24 were excluded because they experienced delays of ≥3 days due to medical reasons or patient’s wish (Fig. 1). Thus, 100 patients were included in the present analyses. Median age was 70 (54–84), 77% had NSCLC, and 63% were women (Table 1).

The observed pathway
Most patients had a CT of the chest and upper abdomen before referral. Referrals were reviewed by an experienced pulmonologist and the first hospital visit including a spirometry and a bronchoscopy was scheduled. Images, pathology results and physical tests were presented at the weekly tumor board meeting during which the need for supplementary diagnostic procedures and treatment decisions were made.

Causes for delayed treatment
We found several factors that led to delayed start of treatment. We have presented the actual pathway for three patients in Fig. 2 to illustrate some of the most common causes for delay. The most important causes for delay were:

1) Disease stage was not correctly assessed before the first hospital appointment took place because the pulmonologist who reviewed the referral letter did not assess that the quality of the initial CT scan was too poor, too old, or missed the upper abdomen (n = 8, caused a delay of median 15.5 days, range: 2–98 days). This was usually pointed out by the chest radiologist, who often did not see the images until the tumor board meeting. Consequently, the radiology report was not completed when the first hospital visit took place (n = 39, caused a delay of median 2 days, range: 1–55 days).

2) Patients were not referred to a PET CT at the first consultation (n = 27, median of 8 days later, range: 1–36 days), partly because the radiology report of the CT scan was not available.

3) Patients were not referred for an exercise test at the first hospital visit (n = 16, median of 10 days later, range: 2–28 days). In total, 21 patients underwent exercise testing.

4) Patients underwent subsequent tissue procedures because an attempt of sampling tumor through bronchoscopy failed when a transthoracic CT guided biopsy was the method that produced a diagnosis (n = 15). The method for obtaining a diagnostic tissue sample was bronchoscopy in 27 cases (at the second attempt in three cases) and a transthoracic needle biopsy in 19 (following a negative bronchoscopy in 15 cases). Fifty-four patients were referred to treatment without a definitive cancer diagnosis (42 to surgery, 11 to stereotactic radiotherapy and one to conventional radiotherapy). Of these, 22 underwent no tissue sampling procedures, 27 underwent one negative bronchoscopy, and two attempts were made in five cases.

5) Need for additional diagnostic procedures due to findings on PET CT (n = 12; FDG upload in

Fig. 1 Patient selection. Preliminary stage was defined as TNM stage according to the baseline CT scan.
mediastinal lymph nodes \((n = 3)\), the thyroid gland \((n = 2)\), parotid gland \((n = 1)\), pharynx \((n = 1)\), small intestine \((n = 1)\), colon \((n = 2)\), heart \((n = 1)\), and genitals \((n = 1)\).

6) Incomplete investigation before the patient was discussed at the tumor board (10 patients were referred to PET CT, and 6 to exercise testing). Thus, the treatment decision was delayed \((n = 16)\).

7) Interval from the hospital received a referral letter until the first hospital appointment exceeded 7 days for unexplained reasons \((n = 50)\). Of these, 18 patients waited 14 days or more.

8) Long waiting time for PET CT. When the study was conducted, patients had to be referred to other hospitals for PET CT, and the median time until the PET CT reports were available was 20.5 days.

---

**Table 1**: Baseline characteristics

| Included \(N = 100\) | Unplanned delay \(n = 24\) | Ineligible of curative treatment \(n = 26\) |
|------------------------|--------------------------|---------------------------------|
| Median age (range)     | 70 (54–84)               | 70.5 (56–86)                    | 81 (58–89) |
| Age ≥ 75 years         | 32 (32%)                 | 9 (38%)                         | 19 (73%) |
| Women                  | 63 (63%)                 | 12 (50%)                        | 13 (50%) |
| Stage I                | 72 (72%)                 | 16 (67%)                        | 10 (38%) |
| Stage II               | 20 (20%)                 | 7 (29%)                         | 8 (31%) |
| Stage III              | 8 (8%)                   | 1 (4%)                          | 3 (12%) |
| Stage IV               |                          |                                 | 5 (19%) |
| Surgery                | 76 (76%)                 | 15 (63%)                        |          |
| Curative radiotherapy* | 8 (8%)                   | 1 (4%)                          |          |
| Stereotactic radiotherapy* | 16 (16%)              | 8 (33%)                         |          |
| Palliative treatment   |                          |                                 | 12 (46%) |
| NSCLC                  | 77 (77%)                 | 18 (75%)                        | 11 (42%) |
| SCLC                   | 6 (6%)                   | 1 (4%)                          | 2 (8%)  |
| Another primary lung cancer | 5 (5%)                | 1 (4%)                          | 1 (4%)  |
| No tissue diagnosis    | 12 (12%)                 | 4 (17%)                         | 12 (46%) |

\*Includes chemo-radiotherapy in limited disease SCLC  
\*In T1-2 N0 NSCLC

---

**Fig. 2**: Patient cases demonstrating some common reasons why treatment was delayed: several procedures were performed when it was evident that the last procedure was most likely to succeed (Case 1); a late PET CT revealed lesions that caused sequential diagnostic procedures (Case 2); unnecessary delays because the pathology reports were not acted upon (and the patients were not informed) until several days after they were completed (Case 1, marked with a stapled line); late referral to PET CT and cardiopulmonary exercise testing (Case 3); long waiting time for pathology report (Case 2 and 3), PET CT (Case 2 and 3), and cardiopulmonary exercise testing (Case 3); and long waiting time for treatment (Case 1).
(range: 7–49). A PET CT scanner was installed in our hospital in October 2013, and the current waiting time is now 7 days or less.

9) Long waiting time from a tissue sampling procedure took place until the pathology report was completed (median of 4.5 days, range: 0–14 days). Furthermore, patients were routinely given an appointment for information about the pathology report 1–2 weeks after the tissue sampling procedure, which caused further delays when the sampling was unsuccessful.

10) Other important delays occurred due to waiting time for cardiopulmonary exercise testing ($n = 9$, median of 11 days, range: 1–19 days); and waiting time for a repeated tissue sampling procedure (median of 8 days, range: 1–14 days).

11) The median interval from referral to treatment until surgery was 13 days (range: 4–48 days), and until radiotherapy 22.5 days (range: 6–37 days).

We also found that two patients were medically operable but received chemo-radiotherapy due to SCLC. In all other patients, there was a medical reason when radiotherapy was chosen instead of surgery.

**Time to treatment**

The median time to treatment was 46.5 days (5–145), and 40% (95% CI: 31 to 50%) of patients started treatment within the recommended 42 days (Fig. 3). When applying the current waiting time for PET CT ($\leq 7$ days), the proportion of patients who could have started timely treatment increased to 48% (95% CI: 39 to 58%) ($p = 0.255$) (Fig. 3).

Based on our analyses, we defined the following optimal pathway:

1) If a CT of the chest and upper abdomen is not performed before, it should take zero days from a referral letter is received until referral for a CT scan.

2) In patients who are considered fit for curative treatment, it should take zero days from the first consultation until referral to PET CT.

3) In patients with reduced pulmonary function it should take zero days from the first consultation until referral for exercise testing.

4) Patients should be discussed at a tumor board meeting immediately after completion of exercise tests and PET CT to a) decide how tissue sampling for both diagnostic and staging purposes should be performed; b) make a treatment decision.

5) It should take zero days from the tumor board meeting until referral to a procedure using a method that is suitable for simultaneous diagnosis and staging.

6) It should take zero days from the tumor board meeting until referral to treatment.

Applying this optimal pathway, current waiting time for PET CT ($\leq 7$ days) and observed timelines for the other procedures, the proportion of patients who could start treatment within 42 days would increase to 80% (95% CI: 72 to 87%) ($p < 0.001$) (Fig. 3), and the number of tissue sampling procedures would have been reduced with 16% (from 112 to 92 procedures). Applying the **Fig. 3** Time to treatment in calendar days from receiving a referral letter for suspected lung cancer in lung cancer patients with stage I-II on the baseline CT scan and who received curative treatment. A) observed timelines; B) estimated timelines when applying current waiting time for PET CT ($\leq 7$ days); C) estimated timelines when applying the optimal sequence of procedures and current waiting times for PET CT. The reference line at 42 days refer to the Norwegian Guidelines for timely lung cancer treatment.
optimal pathway, current waiting time for PET CT and median observed intervals for each diagnostic procedure, 93% patients could have started treatment within 42 days (Fig. 4).

Discussion

We have previously found that few lung cancer patients started treatment within the recommended national timeframes at our hospital [11]. In the present study, we analyzed the individual patients’ pathways in order to investigate the reasons for delay, including patients who presented with stage I-II disease on the baseline CT scan who received curative treatment. We found that only 40% of patients started treatment within the recommended timeframe in Norway of 42 days, and suboptimal planning was an important explanation for this. Specifically, the main reasons were that patients were referred to a PET CT late during the diagnostic workup, leading to unnecessary delay and sequential procedures; the optimal method for tissue sampling was not chosen first, leading to repetition of procedures; and exercise tests were not performed before the patient was discussed at the tumor board meeting, leading to delayed treatment decision. There were long waiting times for PET CT during the study period, but when applying current waiting time for PET CT ($\leq 7$ days), the proportion of patients who could start treatment within 42 days only increased to 48%. Based on our analyses, we defined a more optimal sequence of actions. By applying this optimal pathway and current waiting time for PET CT, the proportion of patients who would have started treatment within 42 days increased to 80% and the number of diagnostic procedures would have decreased with 16%. Thus, implementing a more optimal pathway could improve timeliness of treatment and save resources.

Several interventions aiming at improving the timeliness of diagnostic workup and start of treatment have been proposed - including care pathways; patient navigators; fast-track programs; and different multidisciplinary decision making procedures [14]. Some studies indicate that such interventions may lead to improvement, but most include allocation of more resources and the exact mechanisms leading to improvement are poorly described [15–24]. Some have investigated the impact of different medical approaches. In a randomized trial of patients with suspected stage I-IIIA lung cancer, performing endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) as the first procedure led to fewer procedures and shorter time until a treatment decision was made when compared to bronchoscopy or a transbronchial needle biopsy as the first procedure [25]. Similarly, a prospective study of tumors that based on chest CT were accessible to EBUS-TBNA showed that EBUS-TBNA improved the diagnostic yield when compared to bronchoscopy and transbronchial biopsy [26]. Several studies have shown that delays occur and if the first tissue procedure fails [27–29], complications and costs increases [30], suggesting that procedure for collection of tissue samples should be discussed at a multi-disciplinary tumor board [31].

There are several limitations to our study. It is a single-center study and the mechanisms for delay may not...
necessarily be relevant for other hospitals or other health care systems. E.g., the health care system in Norway is public, and the PET CT availability may have been more limited during the study period than in otherwise comparable health care systems. But even if the reasons for delay may vary between hospitals, we believe that our study presents an approach for analyzing delays that might be useful also in other organizations. Furthermore, we decided to limit our study to stage I-II patients due to the complexity and heterogeneity of patients with more advanced stage and did not include data on patients who underwent similar diagnostic work-up but were not diagnosed with lung cancer. We have not included analyses of time trends due to the significant impact of availability of PET CT. When the scanner was installed at our hospitals, the waiting time for PET CT reports was shortened, but more patients underwent the procedure. Furthermore, there were no organizational changes during the study report that would impact the treatment time.

We are not aware of any internationally accepted definition of an optimal pathway for diagnostic workup for lung cancer. Our definition is only based on what we consider most time-effective and may be questioned. There were quite many bronchoscopies that did not add any information or resulted in a definitive diagnosis of cancer. However, unsuspected endobronchial involvement occurs, and some recommend that a bronchoscopy should be one of the first diagnostic procedures when lung cancer is suspected [32, 33]. Furthermore, it is not always obvious which method for tissue sampling that has a highest chance of success, and bronchoscopy entails less risk of complications than a CT guided trans-thoracic biopsy. We do, however, argue that all relevant imaging including a PET CT scan should be performed before any invasive procedure including bronchoscopy to better plan the procedure and increase the chances for a positive yield from the tissue sampling.

Norwegian guidelines are not explicit on whether PET CT should be done before or after a diagnosis has been confirmed [9]. Access to PET CT is limited, and many patients have to travel long distances for a PET CT. But if reducing time to treatment is the highest priority, our data strongly indicate that a PET CT should be performed as soon as possible after the CT scan in preliminary stage I-II.

Referring patients for treatment before all procedures have been completed may be more controversial. In our cohort, the treatment plan changed in only 2% of cases after PET CT, but will still cause cancellations of planned treatment, which requires good administrative systems to fully utilize the capacity in operating theatres and radiotherapy departments. Finally, the impact on timelines of applying our optimal pathway is simulated and not validated in an intervention trial.

The main strength of our study is that we have performed a comprehensive review of the individual patients’ trajectories from the individual medical records. Most other studies investigating timeliness of lung cancer care, utilize registry data and investigate associations between demographic data, hospital and patient characteristics with timelines [10, 34–41]. Our study group is multidisciplinary (pulmonologists, an oncologist and a gynecologist not involved in diagnosis or treatment of lung cancer), and there were few changes in the staff of pulmonologists who worked at our hospital during the study period.

We believe that our study strongly suggests that the time until start of treatment can be greatly reduced by analyzing current pathways for diagnostic workup and applying a more rational pathway without adding more resources. E.g., the time until the first appointment has later been reduced through better organization. Furthermore, the number of diagnostic procedures would have been reduced if the optimal pathway had been applied, which would reduce the burden on patients and consequently the risk of severe complications. This might be of even greater benefit of patients with delays due to medical reasons (i.e. significant comorbidity) who were excluded from the present study even if they still would not be able to start treatment within 42 days. Still, time until treatment would have been further reduced if waiting time for tissue sampling procedures, radiology- and pathology reports, surgery and radiotherapy were shortened, indicating that at some point, more resources are needed in order to further reduce the time until treatment.

The most common role of tumor board meetings seems to be to discuss treatment alternatives, and thus facilitate a fast and correct treatment [22, 42]. Our study indicate that the patients can in most cases be referred for treatment while the tissue procedures are being performed since the treatment recommendation will change in very few. The tumor board might also play a role in selecting the most correct diagnostic procedures, suggesting that patients should be discussed by a tumor board after the initial imaging and physical examinations have been performed. It is possible, though, that applying our pathway including the early discussion at a tumor board and early referral for treatment is only applicable at larger hospitals. More frequent meetings of the tumor board might reduce the time to treatment even more, but in our cohort, the effect of better planning would have a much greater impact on the timelines.

It remains unclear whether shortening the time until treatment has a positive impact on the treatment outcomes, and one might argue that since the median time to treatment was 46.5 days, there is no benefit of reaching the goal of 42 days. However, the goal is that 70% of patients should start treatment within 42 days. Thus, our
hospital was far behind this goal even for the least complicated patients analyzed in the present study.

Conclusions

Only 40% of preliminary stage I-II lung cancer patients started treatment within the recommended 42 days at our hospital. When applying the current waiting time for PET CT (≤7 days), the proportion increased to 48%. If also a more optimal pathway had been applied, the proportion could increase to 80% and the number of diagnostic procedures could be reduced with 16%.

Abbreviations

CT: Computer tomography; EBUS TBNA: Endobronchial ultrasound transbronchial needle aspiration; PET CT: Positron emission tomography computer tomography; TN TB: Transthoracic needle biopsy

Acknowledgements

Not applicable.

Authors’ contributions

BHG and TS designed the study. TS collected and analyzed the data. All authors (TS, BHG, SS, TA) contributed to the interpretation of the data. BHG and TS were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Funding

The first author received a grant from St Olavs hospital for the conduct of this study. The funding body did not participate in data collection, analysis or interpretation of the data, or in writing the manuscript.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

A passive consent procedure was applied. All patients alive received written information about the study and were given the opportunity to decline participation by completing a form and return it in an enclosed, prepaid envelope. The study and the passive consent procedure were approved by the Regional Committee for Medical and Health Research Ethics in Western Norway (REK Vest (2014/60).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Faculty of Medicine and Health Sciences, Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, PO Box 8905, MTFS, NO-7491 Trondheim, Norway. 2 Department of Gynecology, St. Olavs hospital, Trondheim University Hospital, PO Box 3250, Sluppen, NO-7006 Trondheim, Norway. 3 Faculty of Medicine and Health Sciences, Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, PO Box 8905, MTFS, NO-7491 Trondheim, Norway. 4 Department of Thoracic Medicine, St. Olavs hospital, Trondheim University Hospital, PO Box 3250, Sluppen, NO-7006 Trondheim, Norway. 5 Cancer Clinic, St. Olavs hospital, Trondheim University Hospital, PO Box 3250, Sluppen, NO-7006 Trondheim, Norway.

Received: 11 October 2018 Accepted: 9 September 2019

Published online: 18 September 2019

References

1. Paul C, Carey M, Anderson A, et al. Cancer patients’ concerns regarding access to cancer care: perceived impact of waiting times along the diagnosis and treatment journey. Eur J Cancer Care (Engl). 2012;21(3):321–9. https://doi.org/10.1111/j.1365-2354.2011.01311.x published online first: 23 Nov 2011.

2. Mohammed N, Kestin LL, Grills IS, et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;79(2):466–72. https://doi.org/10.1016/j.ijrobp.2009.11.029.

3. Evenett S, Plumridge N, Herschtal A, et al. The impact of time between staging PET/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer. Radiother Oncol. 2013;106(3):288–91. https://doi.org/10.1016/j.radonc.2013.02.010.

4. Mura T, Shibamoto Y, Baba F, et al. Progression of non-small-cell Lung Cancer during the interval before stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(1):463–7. https://doi.org/10.1016/j.ijrobp.2010.10.001.

5. Lewis NR, Le Jeune I, Baldwin DR. Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway. Br J Cancer. 2009;93(8):905–8. https://doi.org/10.1038/sj.bjc.6602798.

6. Hanna SJ, Munee P, Khall KH. The 2-week wait for suspected cancer: time for a rethink? J Clin Pract. 2005;59(11):1334–9. https://doi.org/10.1111/j.1366-5031.2005.00687.x.

7. Probst HB, Hussain ZB, Andersen O. Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians—a national Danish project. Health Policy. 2012;105(1):65–70. https://doi.org/10.1016/j.healthpol.2011.11.001 published online first: 30 November 2011.

8. Olesen F, Hansen RP, Vedsted P. Delay in diagnosis: the experience in Denmark. Br J Cancer. 2009;101(S2):65–8. https://doi.org/10.1038/sj.bjc.6605383.

9. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølgelse av lungekreft, mesoteliom og thymom. https://helsedirektoratet.no/retningslinjer/nasjonalt-diagnostikk-behandling-og-oppfølging-av-lungetreft-mesoteliom-og-thymom. Accessed 09 Sep 2018. Norwegian.

10. Forrest LF, Adams J, White M, et al. Factors associated with timeliness of post-primary care referral, diagnosis and treatment for lung cancer: population-based, data-linkage study. Br J Cancer. 2014;111(9):1843–51. https://doi.org/10.1038/bjc.2014.472 published online first: 10 September 2014.

11. Stokstad T, Sorhaug S, Amundsen T, et al. Medical complexity and time to lung cancer treatment - a three-year retrospective chart review. BMC Health Serv Res. 2017;17(1):45. https://doi.org/10.1186/s12913-016-1952-y published online first: 2017/03/18.

12. Dettterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–71. https://doi.org/10.1378/chest.08-0078.

13. Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(S):Suppl e166S–e905. https://doi.org/10.1378/chest.12-2395 published online first: 2013/05/10.

14. Ouasrighoanou R, Freeman RK, Khnissi M. Implementing effective and sustainable multidisciplinary clinical thoracic oncology programs. Transl Lung Cancer Res. 2015;4(4):448–55. https://doi.org/10.3978/j.issn.2218-6751.2015.07.05.

15. Fasola G, Rizzato S, Merlo V, et al. Adopting integrated care pathways in non–small-cell lung cancer: from theory to practice. J Thorac Oncol. 2012;7(8):1283–90. https://doi.org/10.1097/JTO.0b013e3182575bff8.

16. Aasebo U, Strom HH, Postmyr M. The lean method as a clinical pathway facilitator in patients with lung cancer. Clin Respir J. 2012;6(3):169–74. https://doi.org/10.1111/j.1752-699X.2011.00271.x published online first: 2011/09/29.

17. Alasmari S, Yao XP, Cain HC, et al. The effect of a lung cancer care coordination program on timeliness of care. Clin Lung Cancer. 2013;14(5):527–34. https://doi.org/10.1016/j.clcc.2013.04.004 published online first: 01 Jul 2013.

18. Brecken P, Kiels BA, Loojien-Salamon MG, et al. Timeliness of lung cancer diagnosis and treatment in a rapid outpatient diagnostic program with combined 18FDG-PET and contrast enhanced CT scanning. Lung Cancer. 2012;75(3):336–41. https://doi.org/10.1016/j.lungcan.2011.08.017 published online first: 22 September 2011.
19. Hunnibell LS, Rose MG, Conneely DM, et al. Using nurse navigation to improve timeliness of lung cancer care at a veterans hospital. Clin J Oncol Nurs. 2012;16(1):29–36. https://doi.org/10.1188/12.CJON.29-36.

20. Lo DS, Zeldin RA, Skarsstrin R, et al. Time to treat: a system redesign focusing on decreasing the time from suspicion of lung cancer to diagnosis. J Thorac Oncol. 2007;2(11):1001–6. https://doi.org/10.1097/JTO.0b013e318158ded66.

21. Connolly M, Phuah S, Steinfort D, et al. Analysis of multidisciplinary lung cancer practice. Intern Med J. 2007;37(11):18–25. https://doi.org/10.1111/j.1445-5994.2006.01237.x [published online first: 2007/01/04].

22. Freeman RK, Van Woerkom JM, VVyverberg A, et al. The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer. Eur J Cardiothorac Surg. 2010;38(1):1–5. https://doi.org/10.1093/ejcts/ezq051.

23. Leo F, Venisnac N, Poudex M, et al. Multidisciplinary management of lung cancer: how to test its efficacy? J Thorac Oncol. 2007;2(1):69–72. https://doi.org/10.1097/JTO.0b013e31801e0f56.

24. Murray PV, O'Brien MER, Sayer R, et al. The pathway study: results of a pilot randomised controlled trial. Lancet Respir Med. 2015;3(4):282–8. https://doi.org/10.1016/S2213-2600(15)00229-6 [published online first: 11 February 2015].

25. Bugalho A, Ferreira D, Eberhardt R, et al. Diagnostic value of endobronchial ultrasound-guided tranbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med. 2015;3(4):282–9. https://doi.org/10.1016/S2213-2600(15)00229-6 [published online first: 11 February 2015].

26. Verma A, Lim AY, Tai DY, et al. Timeliness of diagnosing lung cancer: number of procedures and time needed to establish diagnosis: being right the first time. Medicine (Baltimore). 2015;94(29):e1216. https://doi.org/10.1097/MD.0000000000001216 [published online first: 2015/04/07].

27. Devbhandari MP, Quennell P, Krysiak P, et al. Implications of a negative bronchoscopy on waiting times to treatment for lung cancer patients: results of a prospective tracking study. Eur J Cardiothorac Surg. 2008;34(3):479–83. https://doi.org/10.1016/j.ejcts.2008.05.025 [published online first: 30 July 2008].

28. Navani N, Nankivel M, Lawrence DR, et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: a prospective study. BMC Cancer. 2013;13:130. https://doi.org/10.1186/1471-2407-13-130 [published online first: 2013/03/21].

29. Schiffman M, Quennell P, Krysiak P, et al. Implications of a negative bronchoscopy on waiting times to treatment for lung cancer patients: results of a prospective tracking study. Eur J Cardiothorac Surg. 2008;34(3):479–83. https://doi.org/10.1016/j.ejcts.2008.05.025 [published online first: 30 July 2008].

30. Almeida FA, Casal RF, Jimenez CA, et al. Quality gaps and comparative effectiveness in lung cancer staging: the impact of test sequencing on outcomes. Chest. 2013;144(6):1776–82. https://doi.org/10.1378/chest.13-3046.

31. Ost DE, Niu J, Elting LS, et al. Determinants of practice patterns and quality gaps in lung cancer staging and diagnosis. Chest. 2014;145(5):1097–113. https://doi.org/10.1378/chest.13-1628.

32. Schwarz C, Schonfeld N, Bittner RC, et al. Value of flexible bronchoscopy in the pre-operative work-up of solitary pulmonary nodules. Eur Respir J. 2013;41(1):177–82. https://doi.org/10.1183/09031936.00018612 [published online first: 2012/04/13].

33. Zhang Y, Zhang Y, Chen S, et al. Is bronchoscopy necessary in the pre-operative workup of solitary pulmonary nodules? J Thorac Cardiovasc Surg. 2015;150(1):36–40. https://doi.org/10.1016/j.jtcvs.2015.02.060 [published online first: 2015/04/07].

34. Schultz EM, Powell AA, McMillan A, et al. Hospital characteristics associated with timeliness of care in veterans with lung cancer. J Thorac Oncol. 2008;3(9):951–7. https://doi.org/10.1097/JTO.0b013e3181839b60.

35. Gould MK, Ghaus SJ, Olsson JR, et al. Timeliness of care in veterans with non-small cell lung cancer. Chest. 2008;133(5):1167–73. https://doi.org/10.1378/chest.07-2654 [published online first: 08 Feb 2008].

36. Woman FM, Rubin G, Bankhead C, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. Br J Cancer. 2015. https://doi.org/10.1038/bjc.2015.30 [published online first: 2015/03/04].

37. Benglund A, Holmberg L, Tshelma C, et al. Social inequalities in non-small cell lung cancer management and survival: a population-based study in Central Sweden. Thorax. 2010;65(4):327–33. https://doi.org/10.1136/thx.2009.125914 [published online first: 2010/04/15].

38. Boxer MM, Vinod SK, Shafiq J, et al. Do multidisciplinary team meetings make a difference in the management of lung cancer? Cancer. 2011;117(22):5112–20. https://doi.org/10.1002/cncr.26149.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral/submissions